**Mycobacterium indicus pranii (Mw) Re-Establishes Host Protective Immune Response in Leishmania donovani Infected Macrophages: Critical Role of IL-12**

Anupam Adhikari1, Gaurav Gupta1, Saikat Majumder1, Sayantan Banerjee1, Surajit Bhattacharjee1, Parna Bhattacharya1, Sangeeta Kumari2, Subhadra Halder2, Suchandra Bhattacharyya Majumdar1, Bhaskar Saha2, Subrata Majumdar1*

1 Division of Molecular Medicine, Bose Institute, Kolkata, India, 2 National Centre for Cell Science, Ganeshkhind, Pune, India

**Abstract**

*Leishmania donovani*, a protozoan parasite, causes a strong immunosuppression in a susceptible host and inflicts the fatal disease visceral leishmaniasis. Relatively high toxicity, low therapeutic index, and failure in reinstating host-protective anti-leishmanial immune responses have made anti-leishmanial drugs patient non-compliant and an immuno-modulatory treatment a necessity. Therefore, we have tested the anti-leishmanial efficacy of a combination of a novel immunomodulator, *Mycobacterium indicus pranii* (Mw), and an anti-leishmanial drug, Amphoterin B (AmpB). We observe that Mw alone or with a suboptimal dose of AmpB offers significant protection against *L. donovani* infection by activating the macrophages. Our experiments examining the anti-leishmanial activity of Mw alone or with AmpB also indicate a p38MAPK and ERK-1/2 regulated pro-inflammatory responses. The Mw-AmpB combination induced nitric oxide production, restored Th1 response, and significantly reduced parasite burden in wild type macrophages but not in IL-12-deficient macrophages indicating a pivotal role for IL-12 in the induction of host-protection by Mw and AmpB treatments. In addition, we observed that Mw alone or in combination with suboptimal dose of AmpB render protection against *L. donovani* infection in susceptible BALB/c mice. However, these treatments failed to render protection in IL-12-deficient mice in vivo which added further support that IL-12 played a central role in this chemoimmunotherapeutic approach. Thus, we demonstrate a novel chemo-immunotherapeutic approach - Mw and AmpB crosstalk eliminating the parasite-induced immunosuppression and inducing collateral host-protective effects.

**Introduction**

Leishmaniasis comprises a spectrum of diseases with distinct clinical outcomes caused by the genus *Leishmania*. Depending on the species variation, the clinical manifestation of the disease can be categorized into 3 different types: cutaneous, mucocutaneous and visceral leishmaniasis [1]. Among these different forms of the disease, visceral leishmaniasis (VL) caused by *Leishmania donovani* is the most severe one [2].

A strong immunosuppression ensues following *L. donovani* infection. For example, the parasite impairs free radical (super oxide and nitric oxide) generation [3] and interleukin-12 - a host-protective cytokine [4] - production from macrophages. In contrast, the disease-promoting cytokines, transforming growth factor β (TGF-β) and interleukin (IL)-10 are enhanced in *L. donovani* infection [5,6]. Thus, host protection or disease-promotion is a function of the IL-12 to IL-10 ratio [7], which is primarily regulated by the reciprocal signaling through extracelllular stress-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) [8].

Because the suppression is parasite induced, one obvious mode of therapy is treatment with anti-parasitic drugs. However, because the anti-parasitic immune response is so impaired or deviated that killing of the parasite alone by chemotherapy may not adequately relieve the immunosuppression to re-establish host-protective anti-parasite immune responses. Thus, an adjunct immunostimulatory treatment becomes a necessity. Herein, we describe a combination of an anti-leishmanial drug and a novel immunomodulator that relieves the immune system from the suppression induced by *L. donovani*, an intracellular protozoan parasite that causes high mortality worldwide.

In this study, we have examined the immunomodulatory potential of *Mycobacterium indicus pranii* (Mw) against VL. It is a nonpathogenic, saprophytic cultivable *Mycobacterium* [9] which boosts the immunity against leprosy [10] and tuberculosis [11]. Although *Mw*’s role as a potential immunomodulator has been implied in HIV and cancer, its role- alone or in presence of...
a known anti-leishmanial drug- in resolving *Leishmania*-induced pathogenesis is yet to be explored even though it preferentially activates IFN-γ secreting T cells [12], which is critical for controlling *Leishmania* survival in vivo [13].

Among the recent anti-leishmanial drugs, Amphotericin B (AmpB), a polyene antibiotic, is regarded as the second-line of treatment for *L. donovani* infection [14]. Persistent problem of acute toxicity and low therapeutic index limits the use of AmpB. Recently, alternative approaches such as AmpB-lipid formulations (Ambisome and Amphocil) have been developed with reduced toxicity and an improved therapeutic index for treatment of VL [15]. On the other hand, because an immunotherapy requires removal of the suppression and establishing the *Leishmania*-specific immune responses, we have combined the use of *Mw* and AmpB in experimental *L. donovani* infection. The novelty in our approach lies in the fact that *Mw* induces collateral host-protective effects while the AmpB chemotherapy eliminates the parasite and thereby the parasite-induced immunosuppression.

**Results**

**Determination of the *Mw*, AmpB and *Mw* plus AmpB Doses for Treatment of Macrophages**

Because AmpB and *Mw* may have their own cytotoxic effects on host cells and because these two were aimed to be used at suboptimal doses, we first determined the non-cytotoxic and the sub-optimal doses for these two agents. It was observed that the treatment of uninfected and infected macrophages with *Mw* at doses of 10^7 cells/ml or with AmpB (0.5 μg/ml) reduced cell survivability by less than 10% whereas lower doses of *Mw* (10^6–10^5) and AmpB (0.01–0.10 μg/ml) had no cytotoxic effects on both uninfected and infected macrophages (data not shown). It was observed that *Mw* at a dose of 10^7 cells/ml provided significant protection against *L. donovani* infection corresponding to 67% and 72% parasitic clearance at 24 h and 48 h respectively, in comparison to infected macrophages (Figure 1A). AmpB doses ranging from 0.01 to 0.1 μg/ml showed insignificant parasitic clearance (Figure 1B). These suboptimal doses of AmpB (0.01, 0.02, 0.05, 0.07, 0.1 μg/ml) combined with 10^7 cells/ml dose of *Mw* and were used to treat *L. donovani*-infected macrophages. Compared to the infected macrophages, intracellular parasite count was significantly reduced in parasitized macrophages treated with a combination of *Mw* (10^7) and 0.1 μg/ml dose of AmpB corresponding to 94% and 96% parasitic clearance at 24 h (Figure 1C) and 48 h (Figure 1D) post-infection. Similarly, the cell wall of *Mw* (2 μg/ml) reduced macrophage survivability by less than 10% (Figure 1E) but reduced parasite load in a dose-dependent manner (Figure 1F). Based on these studies, we thus deduced the non-cytotoxic and sub-optimal doses of *Mw* and AmpB that were used in this study.

### Mw and AmpB Enhanced NO Production by *Leishmania*-infected Macrophages

Because reactive oxygen and nitrogen species are two important leishmanicidal molecules, we examined if *Mw* contributed to *L. donovani* elimination by inducing NO. It was observed that treatment of infected macrophages with *Mw* increased nitrite production by 7-fold in comparison with the untreated control. Treatment of the infected macrophages with *Mw* plus AmpB (0.1 μg/ml) showed 10-fold increase in the NO generation whereas treatment with AmpB (0.1 μg/ml) alone did not induce significant nitrite production (Figure 2A). These results corroborated with the significantly increased expression of iNOS2 mRNA in *Mw* or *Mw* plus AmpB treated *L. donovani*-infected macrophages (Figure 2B) suggesting the requirement for NO in the *Mw*-mediated *Leishmania* killing. Indeed, pretreatment of macrophages with L-NMMA, a competitive inhibitor of iNOS2 synthase, strongly inhibited the anti-leishmanial activity of *Mw* or *Mw* plus AmpB (Figure 2C) but *Mw* failed to induce significant ROS in infected macrophages (Data not shown). These data indicate to NO-mediated anti-leishmanial functions of *Mw*.

### Mw Enhances Th1 Promoting Cytokine Production from *Leishmania*-infected Macrophages

Because host-protective anti-leishmanial response is associated with IL-12-dependent Th1 response [16] but *Leishmania*-infected macrophages augment Th2 response [17], we evaluated whether *Mw* treatment of parasitized macrophages induced a Th1-promoting cytokine response. Indeed, IL-12 production was significantly up-regulated in *Mw*-treated control and infected macrophages as compared with untreated infected macrophages (Figure 3A). A similar profile was observed with TNF-α as well (Figure 3B). In contrast, IL-10 and TGF-β levels were significantly less in *Mw*-treated macrophages as compared with infected macrophages; treatment with *Mw* plus AmpB (0.1 μg/ml) reduced IL-10 and TGF-β productions further (Figure 3C–D). The observed profile of the *Mw*-induced cytokines was confirmed by studying mRNA expression by quantitative Real-Time PCR (Figure 3E). These results suggested that *Mw* alone or with AmpB (0.1 μg/ml) up-regulated Th1-promoting cytokines in infected macrophages.

### MAPK Signaling Regulates the Protective Responses in *Mw* Treated Macrophages

Because *Leishmania* suppresses the host-protective responses such as expression of iNOS2 and pro-inflammatory cytokines by modulating p38MAPK and ERK1/2 [8], we tested whether *Mw* altered p38MAPK and ERK1-2 phosphorylation in infected and uninfected macrophages. We observed that ERK-1/2 phosphorylation, which is associated with IL-10 production [8], was lower in *Mw*-treated control and parasitized macrophages (Figure 4A). Similar changes in ERK-1/2 and p38MAPK was also observed in control and parasitized macrophages treated with *Mw* plus AmpB (Figure 4B). We further studied the changes in *Mw*-mediated leishmanicidal activity in presence of p38MAPK and ERK-1/2 inhibitors. Pretreatment with SB203580, a p38MAPK inhibitor, increased parasite load (Figure 4C) but reduced NO (Figure 4B) and IL-12 production (Figure 4E) in *Mw*-treated parasitized macrophages as compared with infected macrophages. In contrast, pretreatment with PD098059, ERK1/2 inhibitor, significantly reduced parasite load but up-regulated IL-12 production and NO generation in *Mw*- or *Mw* plus AmpB-treated parasitized macrophages (Figure 4C–E). These results indicate that *Mw* works by modulation of MAPK pathways.

Anti-leishmanial Effects of *Mw* is Predominantly Mediated by IL-12

Because we observed *Mw* significantly increased the production of IL-12, we evaluated the host-protective response in IL-12-deficient macrophages. *Mw* treatment failed to reduce parasite load from IL-12-deficient macrophages (Figure 5A). IL-12-deficient macrophages were also deficient in *Mw*-induced NO generation (Figure 5B) and TNF-α expression (Figure 5C) but had higher IL-10 (Figure 5D-F) and TGF-β (Figure 5E-F). These results indicate the requirement for IL-12 in *Mw*-mediated protection in *L. donovani*-infected macrophages.
**Mw Significantly Reduces Hepatic and Splenic Parasite Burden in BALB/c Mice**

Because *Mw* treatment of macrophages induced responses that associate with host-protection, we evaluated the efficacy of *Mw* treatment in *Leishmania*-infected BALB/c mice. Five groups of *L. donovani*-infected BALB/c and IL-12 p40^−/−_ mice were treated with PBS or heat-killed *Mw* (10^6_ cells/ml), suboptimal dose of AmpB (2.1 mg/kg body weight) and *Mw* (10^6_ cells) along with AmpB (0.7 mg/kg body weight) daily for 3 consecutive days beginning 15 days after infection. Mice were sacrificed on day 56 after infection and the splenic and hepatic LDU were determined. We observed that during *Mw* treatment the hepatic and splenic LDU were reduced by 60% and 65%, respectively, whereas *Mw* plus AmpB reduced 94% and 96% parasites from liver and spleen, respectively. In contrast, hepatic and splenic LDU were not reduced significantly in IL-12 knock mice after treatment with *Mw* or *Mw* along with suboptimal dose of AmpB. These results suggest that this chemotherapeutic therapy render protection against VL which depends solely on IL-12 (Figure 6A–B).

**Mw Treatment Induces Th1 Responses in *L. donovani* Infected BALB/c Mice**

Successful cure of *L. donovani* infection requires IFN-γ secretion. This represents a core component of host protective immunity to L. donovani infection. We observed that IFN-γ production from splenocytes of differently treated infected animals as compared with the untreated infected group (Figure 7A, 7E and 7C). Similar enhancement in these cytokines was observed in *Mw* plus AmpB-treated mice as compared with the infected controls (Figure 7D, 7F). Moreover, the splenocytes from *Mw*-treated or *Mw* plus AmpB (sub)-treated mice generated significantly higher quantity of nitrite as compared with the control splenocytes (Figure 7B) corroborating with our above described observations. These observations suggest that *Mw* treatment can render significant protection against *L. donovani* infection in a susceptible host, perhaps by higher expression of iNOS2 (Figure 7G) gene and subsequent synthesis of NO and inducing Th1 response.

Interestingly, *Mw* or *Mw* along with AmpB treatment could not significantly induce TNF-α, IFN-γ and nitric oxide production.

---

**Figure 1. **Mw significantly reduces the intracellular parasitic load (A–D). Peritoneal macrophages, isolated from BALB/c mice, were cultured in 8-chambered glass cover slides with complete RPMI 1640 media followed by infection with *L. donovani* promastigotes (macrophage: parasitic ratio of 1:10) for 4 h. Macrophages were treated with different doses of *Mw* (A) or AmpB (B) for 20 h and 44 h. Intracellular parasites were counted per 100 macrophages after Giemsa staining. Similarly, in a separate experiment, macrophages were infected with *L. donovani* promastigotes followed by treatment with *Mw* (10^7_ cells/ml) along with different doses of AmpB for 20 h and 44 h as indicated in the (C) & (D). Intracellular parasites were counted per 100 macrophages after Giemsa staining. Determination of noncytotoxic dose of *Mw* cell wall and it effect on the parasitic burden in *L. donovani*-infected murine peritoneal macrophages (E–F). Uninfected (UIM) and infected (IM) macrophages were subjected to *Mw* cell wall treatment at specified doses (0.1–20 μg/ml) After 48 h of incubation, cell viability assay was performed using the MTT method (E). Infected (IM) macrophages were treated with different doses of *Mw* cell wall (2–7 μg/ml) for 20 h and 44 h (F). Intracellular parasites were counted per 100 macrophages after Giemsa staining. The experiment was repeated 3 times, yielding similar results and data were expressed as mean ± SD. \( P<0.001, \quad P<0.05 \) compared with infected macrophages and \( *P<0.05 \) compared with *Mw* treated macrophages; paired two-tailed Student’s t-test. doi:10.1371/journal.pone.0040265.g001

---

**Mw Effected Immunotherapy Kills L. donovani**

Macrophages. We evaluated the type of immunological response induced by *Mw* or *Mw* plus AmpB(sub) in *L. donovani* infection in wild type and IL-12 knockout BALB/c mice. To assess if *Mw* induced a host-protective Th1 response, we analyzed the cytokine profile from splenocytes of differently treated infected animals as ELISA and Real-Time PCR. Comparative cytokine profile clearly demonstrated that a high level of IL-10 and a low induction of IL-12, TNF-α and IFN-γ in infected mice. In contrast, *Mw*-treated mice showed highly significant increase in IFN-γ, IL-12 and TNF-α as compared with the untreated infected group (Figure 7A, 7E and 7C). Similar enhancement in these cytokines was observed in *Mw* plus AmpB(sub) treated infected BALB/c mice. It was also observed that IL-10 and TGF-β level was significantly decreased in both *Mw* and *Mw*-AmpB treated mice as compared with the infected controls (Figure 7D, 7F). Moreover, the splenocytes from *Mw*-treated or *Mw* plus AmpB (sub)-treated mice generated significantly higher quantity of nitrite as compared with the control splenocytes (Figure 7B) corroborating with our above described observations. These observations suggest that *Mw* with AmpB (sub) treatment can render significant protection against *L. donovani* infection in a susceptible host, perhaps by higher expression of iNOS2 (Figure 7G) gene and subsequent synthesis of NO and inducing Th1 response.
in IL-12 knock out mice. Therefore, these observations suggest that Mw alone or with AmpB(sub) treatment induced Th1 response depends primarily on IL-12.

Discussion

L. donovani infection inflicts the disease visceral leishmaniasis (VL), which is fatal if left untreated. However, the drugs in use – sodium antimony gluconate, miltefosine and AmpB- are all severely toxic and as a consequence lead to patient non-compliance and emergence of drug-resistant strains [18]. The situation becomes grimmer with HIV-L. donovani co-infection, which is almost untreated. Therefore, an alternative therapeutic approach is a pressing need.

Therefore, we have designed a novel chemo-immunotherapeutic strategy whereby the immunomodulator Mw exerts wider immunostimulatory effects and the anti-leishmanial drug AmpB kills the parasite, withdrawing the parasite inflicted immunosuppression.

In this study, heat killed Mw renders significant anti-leishmanial protection aided further by a suboptimal dose of AmpB (0.1 µg/ml). Studies with T cells have shown that Mw specifically activates high levels of IFN-γ producing Th1 cells in an IL-12-dependent manner, while Th2 cells are unaffected leading to low expression of IL-4 and IL-5 [12]. On the other hand, AmpB having immunomodulatory effects on neutrophils, macrophages, NK cells, T cells and B cells [19–21] induces the production of pro-inflammatory cytokines where higher concentration of AmpB is toxic to host cells leading to cell death via apoptosis [22]. Mw alone or aided further with suboptimal dose of AmpB triggered the release of pro-inflammatory cytokines like IL-12 and TNF-α with much less cytotoxic effects on host cells. Interestingly, the induction of IL-12 both at protein and mRNA level was much more than that of TNF-α. The disease-promoting cytokines IL-10 and TGF-β were down-regulated following treatment with Mw alone or with AmpB. An efficient regulation of pro- and anti-inflammatory cytokines by the action of Mw alone or Mw plus AmpB might regulate the generation of NO. Pro-inflammatory cytokines play a critical role in the induction of NO via iNOS2 during VL [23], whereas IL-10 inhibits NO [8]. NO generation, along with iNOS2 expression, was significantly elevated in Mw or Mw in combination with AmpB-treated parasitized macrophages. This iNOS2-mediated parasite killing by Mw or Mw plus AmpB was found to be severely abrogated in presence of L-NMMA confirming a role for NO in Mw mediated intracellular parasite clearance.

A previous report suggested AmpB induced strong pro-inflammatory response [24] whereas not much is known about Mw mediated alteration in signaling pathways that result in the production of pro-inflammatory cytokines such as IL-12. We have shown that in L. donovani-infected macrophages, the effector response in the form of NO and IL-12, is regulated by the antagonistic regulation of p38MAPK and ERK1/2 signaling pathways. CD40 activates ERK1/2 leading to enhance production of IL-10, which in turn inhibits the activation of p38MAPK during Leishmania infection [8]. Mw alone or aided by suboptimal AmpB restored the impaired p38MAPK phosphorylation in parasitized macrophages and reduced the ERK1/2 phosphorylation. p38MAPK inhibition increased parasite load but impaired NO production and IL-12 secretion. ERK1/2 inhibition followed by Mw-based immunotherapy significantly enhanced NO and IL-12 secretion and reduced intracellular parasite load. Our data corroborate with such reciprocity in the signaling pathway induced effector functions [8] and suggest that AmpB works through the same signaling pathway.

Figure 2. Mw induces the nitrite generation in Leishmania donovani infected murine macrophages (A–C). (A) Uninfected (UIM) and infected (IM) macrophages were treated with Mw (10^7cells/ml), suboptimal dose of AmpB (0.1 µg/ml) and Mw plus AmpB (0.1 µg/ml). After 48 hours the cell free supernatant were collected and nitrate generation were measured in different sets. (B) mRNA expression of iNOS2 from similar experiments were determined by Real Time -PCR, (C) Macrophages cultured in chambered cover slides were treated with or without L-NMMA (0.4 mmol/L) for 1 h prior to infection followed by treatment with Mw and AmpB for 20 h and 44 h. After that, cover slips were stained with Giemsa and assessed for intracellular parasites number. L-NMMA significantly inhibited parasite killing activity of Mw and the similar type of inhibition was also observed in case of combination of Mw plus AmpB treatment. Results are presented as mean values. The experiment was repeated 3 times, yielding similar results and data were expressed as mean ± SD. **P<0.01 compared with infected macrophages and ***P<0.05 compared with Mw treated macrophages; paired two-tailed Student’s t-test. doi:10.1371/journal.pone.0040265.g002
Previous studies with IL-12 deficient mice or IL-12 neutralization reported increased parasite load and transient decrease in IFN-\(\gamma\), TNF-\(\alpha\) and iNOS2 production suggesting the indispensability of IL-12 in the induction of protective immunity against \textit{L. donovani} infection [25]. Likewise, in our experiments as well, \textit{Mw} or \textit{Mw}-AmpB failed to generate any significant effector response such as NO and TNF-\(\alpha\) production in IL-12 deficient macrophages. On the contrary, the disease-promoting cytokines- IL-10 and TGF-\(\beta\) were significantly induced in IL-12-deficient macrophages leading to higher intracellular parasite count.

Figure 3. \textit{Mw} shifts the cytokine response from Th2 to Th1 (A–E). Uninfected (UIM) or \textit{Leishmania} infected (IM) macrophages (2 \(\times\) 10^6 cells/ml) were treated with \textit{Mw} (10^5 cells/ml), AmpB (0.1 \(\mu\)g/ml), or \textit{Mw} plus AmpB (0.1 \(\mu\)g/ml) for 20 h. Levels of IL-12p70 (A), TNF-\(\alpha\) (B), IL-10 (C) and TGF-\(\beta\) (D) in the culture supernatant of differently treated sets were evaluated by sandwich ELISA, as described in Materials and Methods. (E) Total RNA was extracted from similarly treated uninfected or infected macrophages using TRIZOL and Real Time-PCR was performed to study mRNA expression of different pro-inflammatory and anti-inflammatory cytokines. Results are presented as mean values. The experiment was repeated 3 times, yielding similar results and data were expressed as mean \(\pm\) SD. \(\ast P<0.001\), \(\ast\ast P<0.01\) compared with infected macrophages and \(\ast\ast\ast P<0.05\) compared with \textit{Mw} treated infected macrophages; paired two-tailed Student’s t-test.

doi:10.1371/journal.pone.0040265.g003
The *in vivo* studies with *Mw* alone or in combination with AmpB were performed to test the therapeutic potential of this chemoimmunotherapeutic approach. *In vivo* experiments demonstrated that treatment with *Mw* alone or in combination with AmpB significantly restricted the parasite growth in liver and spleen in *L. donovani*-infected mice. A strong induction of IFN-γ, IL-12 and TNF-α by *Mw* alone or in combination with AmpB in infected mice indicates the ability of this therapy to induce a Th1 response. Moreover, this therapy involving *Mw* and AmpB led to the restoration of the T cell proliferative response in *L. donovani*-infected BALB/c mice. In addition, a sharp decrease in IL-10 and TGF-β production was observed in *L. donovani*-infected mice indicated the potential of this therapy in shifting the balance from Th2 to Th1 response. Interestingly, all the protective effects of this chemotherapeutic approach were completely abrogated in IL-12 knockout mice. Altogether, these results indicated the host-protective anti-leishmanial function of this chemo-immunotherapeutic strategy was strictly dependent on IL-12.

Thus, a drug-immune synergism provides the most striking host-protective effect. In conclusion, we report a novel chemo-

---

**Figure 4.** *Mw* mediated effector function depends on the reciprocal activation of p38 mitogen-activated protein kinase (p38MAPK) and extracellular signal-regulated kinase (ERK)-1/2 (A–E). Uninfected (UIM) or *Leishmania* infected macrophages (IM) were treated for 0, 5, 15, 45 and 60 minutes with *Mw* (A) or *Mw* plus AmpB (0.1 μg/ml) (B). Western blotting was performed with anti-pERK1/2, pp38MAPK, p38MAPK, and ERK1/2 as described in Materials and Methods. (C) Macrophages were pretreated with SB203580 (SB; 10 μg/ml) or PD098059 (PD; 100 μmol/L) (See Materials and Methods) for 2 h followed by *Leishmania* infection and then treated with *Mw* or *Mw* plus AmpB for 24 h or 48 h. Intracellular parasites were counted per 100 macrophages after Giemsa staining. Pretreatment with SB203580 significantly inhibited *Mw* or *Mw* plus AmpB mediated parasite killing, compared to corresponding *Mw* or *Mw* plus AmpB treated infected controls. *P*<0.001 for SB203580; paired two-tailed Student’s t-test. (D) Macrophages (1 × 10⁶ cells/ml) cultured in a 24-well plate were pretreated and infected as described in Figure 3. For maximum nitrite generation, cell-free supernatants were collected after 48 h of infection and subjected to Griess assay method as described in the Materials and Methods. (E) Cell free supernatants were collected after 24 h from macrophage culture, pretreated and infected as described previously, for estimation of IL-12 release by sandwich ELISA. Pretreatment with SB203580 significantly inhibited *Mw* or *Mw* plus AmpB mediated NO generation and IL-12 release, compared to corresponding *Mw* or *Mw* plus AmpB treated infected controls. *P*<0.001 compared to infected macrophages. *P*<0.001 compared to uninfected macrophages; paired two-tailed Student’s t-test. On the lower panel (A) and (B) respective densitometry data is shown. The experiments were repeated thrice, yielding similar results and data were expressed as mean ± SD.

doi:10.1371/journal.pone.0040265.g004
IL-12 is critical for Mw and suboptimal dose of AmpB mediated protection against Leishmania donovani infection (A–F). (A) Peritoneal macrophages, isolated from BALB/c and IL-12p40⁻/⁻ mice, were cultured in eight chambered cover slides and infected with L. donovani. Infected macrophages were treated with Mw (10⁷/ml) or Mw plus AmpB (0.1 μg/ml) for 20 h and 44 h and intracellular parasites were counted per 100 macrophages after Giemsa staining. The experiment was repeated four times, yielding similar results and data were expressed as mean ± SD. (B) Uninfected or Leishmania infected BALB/c and IL-12p40⁻/⁻ peritoneal macrophages (10⁶ cells/ml) were treated with Mw (10⁷ cells/ml), AmpB (0.1 μg/ml), and IFN-γ (10 units/ml) for 20 h and 44 h, and nitrite production was measured. The experiment was repeated four times, yielding similar results. Data were expressed as mean ± SD.
immunotherapeutic strategy that can be applicable to not only *Leishmania* but also in many other infections.

**Materials and Methods**

**Ethics Statement**

This study was carried out in strict accordance with the recommendations of the Institutional Animal Ethical Committee. All experimental animal protocols received prior approval from the Institutional Animal Ethical Committee (Bose Institute, Registration Number: 95/99/CPCSEA).

**Reagents and Chemicals**

RPMI-1640, M-199 (M199), penicillin-streptomycin, L-N-monomethyl arginine (L-NMMA), SB203580, PD98059 and TRI Reagent were from Sigma (St Louis, MO, USA). dNTPs, RevertAidTM M-MuLV Reverse Transcriptase, oligo dT, RNase inhibitor and other chemicals required for cDNA synthesis were from Fermentas (USA). TRI Reagent were from Sigma (St Louis, MO, USA). dNTPs, RevertAidTM M-MuLV Reverse Transcriptase, oligo dT, RNase inhibitor and other chemicals required for cDNA synthesis were from Fermentas (USA).

**Animals, Parasites and Mycobacterium w (Renamed as Mycobacterium Indicus Pranii)**

[LOOSEST]BALB/c mice were from the National Center for Laboratory Animal Sciences, Hyderabad, India. IL-12-deficient mice (IL-12p40<sup>−/−</sup>, BALB/c background) were from Jackson Laboratories (Bar Harbor, ME). *Leishmania* strain AG83 (MHOM/IN/1983/AG83) was maintained in vitro in M199-10% FCS. Experiments were performed with stationary phase promastigotes. Dr. B. M. Khamer (Cadila Pharmaceuticals Limited, Gujarat, India) generously gifted the *Mw* (Heat killed *Mw*, Immuvac, 0.6 ml vial).

**Isolation of Peritoneal Macrophages and Infection with Leishmania**

Macrophages were isolated from thioglycolate (i.p., 4% w/v, 1 ml/mouse) elicited peritoneal lavage of 6–8 weeks old male BALB/c and IL-12p40<sup>−/−</sup> mice [8]. BALB/c or IL-12p40<sup>−/−</sup> derived macrophages were cultured on 8-chambered glass cover slides (10<sup>4</sup>cells/well) in RPMI-FCS and were infected with *Leishmania* promastigotes at a 1:10 macrophage to parasite ratio for 4 h, followed by extracellular promastigote removal. The infected macrophages were treated with either *Mw* (10<sup>5</sup> cells/ml) or indicated doses of AmpB (0.01–0.5 μg/ml) or their combination at 37°C for 24 h or 48 h. Cells were washed, fixed in methanol and Giemsa-stained for enumeration and expression of parasite load as amastigotes/100 macrophages.

**Cytotoxicity Assay by MTT**

Macrophage in 96-well tissue culture plates (Tarson) incubated with *Mw* (10<sup>5</sup>–10<sup>8</sup> cells/ml), AmpB (0.01–2 μg/ml), *Mw* (10<sup>7</sup> cells/ml)+AmpB (0.01–0.1 μg/ml) and *Mw* cell wall at concentrations ranging from (0.01–20 μg/ml) were cultured in RPMI-1640 supplemented with 10% FCS for 48 h. The medium was replaced with fresh RPMI (without Phenol Red) containing 1 mg/ml MTT. Cells were incubated at 37°C for 3 h, the untransformed MTT was removed and 50 μl of 0.04 M HCl-isopropanol solution was added, incubated for 3 h, aspirated and the absorbance was measured at 540 nm (490 nm correction).

**Figure 6. Treatment with Mw or Mw plus AmpB (sub) causes complete clearance of hepatic and splenic parasitic burden of infected BALB/c mice (A–B).** BALB/c and IL-12 knockout mice were infected with *L. donovani*, followed by treatment with either phosphate buffered saline (PBS; control), *Mw* (10<sup>5</sup>cells/100 μl), suboptimal dose of AmpB (2.1 mg/kg body weight) and *Mw* plus AmpB (suboptimal). Mice were sacrificed on day, 56 after infection. Untreated, infected mice were used as controls. Levels of parasitic burden in liver (A) and spleen (B) samples were expressed in Leishman Donovan Units (LDU). Data were expressed as mean ± SD (n=4 mice per group) *P<0.001, **P<0.01 compared with infected mice and ***P<0.05 compared with *Mw* treated infected mice; paired two-tailed Student’s t-test.

doi:10.1371/journal.pone.0040265.g006
added to each well. 15 min later, absorbance was measured on an automatic plate reader (Thermolab System Multiskan Ex) at a reference wavelength of 690 nm and test wavelength of 650 nm.

Cell Wall Isolation from Mw

The cell wall fraction was prepared by the following procedure [27]. Mw cells were suspended in cold saline. This suspension was then processed in a cell fractionator and centrifuged at 800 × g to remove unbroken whole cells. The supernatant was centrifuged at

Figure 7. Mw induced Th1 response and NO generation in L. donovani infected BALB/c mice (A–F). Splenocytes from infected and differently–treated mice, as mentioned in figure 6 legend, were isolated on 56 days after infection, plated aseptically (2 × 10⁵ cells/well), and stimulated with 10 µg/ml soluble leishmanial antigen (SLA) for 48 h. Interferon γ (IFN-γ) (A), nitric oxide (B), Tumor necrosis factor α (TNF-α) (C), Interleukin 10 (IL-10) (D) Interleukin 12 (IL-12) (E) and Tumor growth factor β (TGF-β) (F) from the culture supernatants of the indicated treatment groups were determined by enzyme-linked immunosorbent assay and the Nitric Oxide Colorimetric Assay kit, respectively. Real-Time polymerase chain reaction (PCR) analysis was performed from similar experimental sets to determine proinflammatory (IFN-γ, IL-12p70, TNF-α), anti-inflammatory cytokines (IL-10, TGF-β) and iNOS2 mRNA expression (G, H). Results are from three independent experiments. Data are means ± standard deviations of values from 3 independent experiments that yielded similar results. *P < 0.001, **P < 0.01 compared with infected mice and ***P < 0.05 compared with Mw treated infected mice; paired two-tailed Student’s t-test.

doi:10.1371/journal.pone.0040265.g007
15,000×g for 60 min to obtain the soluble cytoplasm and sediment consisting predominantly of cell wall. The crude cell wall fraction was suspended in sterile water and centrifuged at 800×g to remove unbroken whole cells again.

**Nitrite Generation Assay**

Nitrite accumulation in culture supernatants was assessed by the Griess reaction [20] using the Nitric Oxide Assay Kit (Boehringer-Mannheim Biochemicals, Indianapolis, IN, USA). For each assay, macrophages (10^6 cells/ml) were cultured in 24-well tissue culture plates. Cell-free supernatants were collected from different intensity units.

Fluorometric measurements were expressed in mean fluorescence wavelength of 510 nm and an emission wavelength of 525 nm.

20 min in the dark. Relative fluorescence was measured in cubated with H<sub>2</sub>DCFDA (2 μM) at room temperature for 20 min in the dark. Relative fluorescence was measured in a Perkin-Elmer LS50B Spectrofluorometer at an excitation wavelength of 510 nm and an emission wavelength of 525 nm. Fluorometric measurements were expressed in mean fluorescence intensity units.

**Cytokine Enzyme-linked Immunosorbent Assay (ELISA)**

Cytokines in the culture supernatants were assayed using the ELISA kits (R&D systems, Minneapolis, MN or BD Pharmingen, San Diego, CA) following the manufacturer’s instructions.

**Isolation of RNA and Real-time Polymerase Chain Reaction**

RNA was isolated according to the standard protocol [30] and reverse transcribed using Revert Aid M-MuLV reverse transcriptase (Fermentas). Real-time polymerase chain reaction (PCR) was performed using SYBR Green mix and the ABI 7500 real-time PCR system (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference.

Sequences of the PCR primers are listed in Table 1. The reaction conditions consisted of an initial activation step (5 min at 95 °C) and cycling step (denaturation for 30 s at 94 °C, annealing for 30 s at 58 °C, and extension for 1 min at 72 °C for 40 cycles), after which melt curve analysis was performed. Detection of the dequenched probe, calculation of threshold cycles, and further analysis of these data were done using Sequence Detector software (version 1.4; Applied Biosystems).

**Preparation of Cell Lysate and Immunoblot Assay**

Cell lysates were prepared as described earlier [31]. Equal amount of protein in each lane was subjected to SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked overnight with 3% BSA in Tris-saline buffer (pH 7.5) and immuno-blotting was performed to detect the phosphorylated or de-phosphorylated forms of p38MAPK and ERK-1/2 [31]. Immunoblots and DNA gel were analyzed on GS-700 imaging densitometer and Molecular Analyst software (version 1.5, Bio-Rad, Hercules, CA).

**References**

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873–882.
2. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244–249.

**Table 1. Primers used in Real Time -PCR assay.**

| Gene  | Primer sequence                                                                 |
|-------|-------------------------------------------------------------------------------|
| il-10 | Forward 5'-CGGAGAGACCAA TAACCTG-3'                                             |
|       | Reverse 5'-CATTCGCGTAAAGG CTG-3'                                              |
| il-12p40 | Forward 5'-CAATCAAGACCACTGA CGAG-3’                                           |
|       | Reverse 5'-TACTCCAGGTCCGCAC-3’                                                |
| ifn-γ | Forward 5'-GGATATCCTGGGAAACTG GC-3’                                           |
|       | Reverse 5'-CGACCTCTTCT GCGTCTCT-3’                                            |
| inos2 | Forward 5’-CCCTTGAGAAGGT CTGCGAGACG-3’                                       |
|       | Reverse 5’-GGCTGTCAGAGCT CCGTATGG-3’                                         |
| INF-α | Forward 5’-G GCAGGTTCACTTG GAGTCTGGG-3’                                       |
|       | Reverse 5’-ACATTCGGAGCTCGA CCTGAGTTCG-3’                                     |
| tgf-β | Forward 5’-GGATACCAACTATTGCTCCGGTCTC-3’                                      |
|       | Reverse 5’-AGGCTCCAATAATG GCGAGGCTC-3’                                      |
| gapdh | Forward 5’-CAGGCTGTCGGCAGCAGTCA-3’                                           |
|       | Reverse 5’-AGGGGAAAGATGG GGAGTGTGC-3’                                        |

**Statistical Analysis**

The in vitro cultures were performed in triplicate and a minimum of 4 mice were used per group for in vivo experiments. The data, represented as mean ± standard deviations (SD), were from one experiment that was performed at least three times. A paired two tailed Student’s t-test was employed to assess for statistical significance and p values of <0.05 were considered statistically significant.

**Acknowledgments**

We are grateful to Director, Bose Institute (Kolkata) for his continuous encouragement. We cordially thank Mr. Debasish Majumdar and Mr. Prabal Gupta for their technical assistance.

**Author Contributions**

Conceived and designed the experiments: AA Subrata Majumdar BS. Contributed reagents/materials/analysis tools: Subrata Majumdar SBM. Performed the experiments: AA GG Saikat Majumder S. Benerjee S. Wrote the paper: AA Subrata Majumdar BS. Wrote the paper: Subrata Majumdar BS. Contributed reagents/materials/analysis tools: Subrata Majumdar SBM. Performed the experiments: AA GG Saikat Majumder S. Benerjee S. Wrote the paper: AA Subrata Majumdar BS. Wrote the paper: Subrata Majumdar BS.

**Trends in Parasitology**

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873–882.
2. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244–249.
3. Stenger S, Donhauser N, Thuring H, Rollinghoff M, Bogdan C (1996) Reactivation of latent Leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 183: 1501–1514.
4. Rad, Hercules, CA).
4. Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, et al. (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30: 834–839.

5. Rodrigues V Jr, Silva da, Santama J, Campos Neto A (1998) Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis. Infect Immun 66: 1233–1236.

6. Bogdan C, Vodovotz Y, Nathan CF (1991). Macrophage deactivation by Interleukin-10. J Exp Med 174: 1549–1555.

7. Gupta G, Bhattacharyya S, Bhattacharya S, Bhattacharya P, Adhikari A, et al. (2009) CXCR chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response. J Infect Dis 200: 1300–1310.

8. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B (2004) Reciprocal CD10 signals through p38MAPK and ERK-1/2 induce counter-acting immune responses. Nat Med 10: 540–544.

9. Reddi PP, Amin AG, Khandekar PS, Talwar GP (1994) Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain. Int J Lepr Other Mycobact Dis 62: 229–236.

10. Zaher SA, Mukherjee R, Ramkumar B, Misra RS, Sharma AK, et al. (1993) Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 167: 401–410.

11. Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, et al. (2009) Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun 77: 223–231.

12. Singh HG, Mukherjee R, Talwar GP, Kauffman SH (1992). In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infect Immun 60: 257–263.

13. Alexander J, Bryson K (2005) T helper 1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99: 17–23.

14. Berman JD, Kisonski G, Chapman WL, Waits VB, Hanson WL (1992) Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother 36: 1978–1980.

15. Davidson RN, Croft SL, Scott A, Maini M, Moody AH, et al. (1991) Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 338: 1061–1062.

16. Taylor A, Murray HW (1993) Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin 12 in experimental visceral leishmaniasis in interferon-gamma-deficient mice. J Exp Med 185: 1231–1239.

17. Chakkalath HR, Titus RG (1994) Leishmania major-parasitized macrophages augment Th2-type T cell activation. J Immunol 153: 4378–4387.

18. Murray HW (2000) Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 4: 136–177.

19. Little JR, Plat EJ, Kotler-Brajburt J, Medoff G, Kobayashi GS (1978) Relationship between the antibiotic and immunoadjuvant effects of amphotericin B methyl ester. Immunochemistry 15: 219–224.

20. Little JR, Wolf JE (1987) Immunologic effects of Amphotericin B. Clin Immunol News 8: 183–185.

21. Sanchis P, Priimi D, Cazenave PA (1986) B cell triggering properties of a nontoxic derivative of amphotericin B. J Immunol 137: 2156–2161.

22. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A (1995) Infection-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycose 38: 459–465.

23. Defrebech A, Schindler H, Rollinghoff M, Yokoyama WM, Bogdan C (1999) Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951–953.

24. Matsuo K, Hotokezaka H, Ohara N, Fujimura Y, Yoshimura A, et al. (2006) Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol Immunol 50: 337–347.

25. Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, et al. (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30: 834–839.

26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.

27. Azuma I, Yamamura Y, Fukushima K (1968) Fractionation of mycobacterial cell wall isolation of arabinose mycolate and arabinogalactan from cell wall fraction of Mycobacterium tuberculosis strain Aoyama B. J Bacteriol 96: 1893–1897.

28. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126: 131–138.

29. Schreck R, Basuerle PA (1994) Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-kappa B. Methods Enzymol 234: 151–163.

30. Ghosh S, Bhattacharyya S, Bhattacharya P, Adhikari A, et al. (2009) CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response. J Infect Dis 200: 1300–1310.

31. Gupta G, Bhattacharjee S, Bhattacharya P, Adhiborn P, Adhikari A, et al. (2007) Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Scand J Immunol 66: 671–683.